Immunophenotyping of leukemia

Journal of Immunological Methods

Volumn 243, Issue 1-2, 2000, Pages 59-75

  Campana, Dario ^a,b,c   Behm, Frederick G ^a,b  

^a St Jude Children's Research Institute   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Flow cytometry; Immunophenotype; Leukemia; Prognostic indicators; Residual disease

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CELL ANTIGEN; CELL SURFACE MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FIBRINOGEN RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; FLUOROCHROME; GLYCOPHORIN A; HLA DR ANTIGEN; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; MYELOPEROXIDASE; RHODAMINE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; CELL DIFFERENTIATION; CELL LINEAGE; CELL MEMBRANE PERMEABILITY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA REMISSION; LYMPHOPROLIFERATIVE DISEASE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; T CELL LEUKEMIA;

EID: 0034699377     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00228-3     Document Type: Article

References (136)

1. Abshire T.C., Buchanan G.R., Jackson J.F., Shuster J.J., Brock B., Head D., Behm F., Crist W.M., Link M., Borowitz M. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia. 6:1992;357.
2. Adriaansen H.J., Jacobs B.C., Kappers-Klunne M.C., Hahlen K., Hooijkaas H., van Dongen J.J. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia. 7:1993;472.
3. Adriaansen H.J., te Boekhorst P.A., Hagemeijer A.M., van der Schoot C.E., Delwel H.R., van Dongen J.J. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood. 81:1993;3043.
4. Almeida J., Orfao A., Ocqueteau M., Mateo G., Corral M., Caballero M.D., Blade J., Moro M.J., Hernandez J., San Miguel J.F. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br. J. Haematol. 107:1999;121.
5. Arber D.A., Glackin C., Lowe G., Medeiros L.J., Slovak M.L. Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. Am. J. Clin. Pathol. 107:1997;68.
6. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R., Schiffer C.A., Bloomfield C.D. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 90:1997;1643.
7. Baruchel A., Cayuela J.M., Ballerini P., Landman-Parker J., Cezard V., Firat H., Haddad E., Auclerc M.F., Valensi F., Cayre Y.E., Macintyre E.A., Sigaux F. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br. J. Haematol. 99:1997;101.
8. Behm F.G., Smith F.O., Raimondi S.C., Pui C.H., Bernstein I.D. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood. 87:1996;1134.
9. Behm F.G., Raimondi S.C., Frestedt J.L., Liu Q., Crist W.M., Downing J.R., Rivera G.K., Kersey J.H., Pui C.H. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood. 87:1996;2870.
10. Behm F.G., Raimondi S.C., Schell M.J., Look A.T., Rivera G.K., Pui C.H. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood. 79:1992;1011.
11. Beishuizen A., Verhoeven M.A., Van Wering E.R., Hahlen K., Hooijkaas H., van Dongen J.J. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood. 83:1994;2238.
12. Bell P.B., Rooney N., Bosanquet A.G. CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase. Cytometry. 38:1999;102.
13. Ben-Bassat I., Gale R.P. Hybrid acute leukemia. Leuk. Res. 8:1984;929.
14. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br. J. Haematol. 78:1991;325.
15. Borella L., Casper J.T., Lauer S.J. Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse. Blood. 54:1979;64.
16. Borowitz M.J., Bray R., Gascoyne R., Melnick S., Parker J.W., Picker L., Stetler-Stevenson M. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry. 30:1997;236.
17. Borowitz M.J., Hunger S.P., Carroll A.J., Shuster J.J., Pullen D.J., Steuber C.P., Cleary M.L. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 82:1993;1086.
18. Borowitz M.J., Shuster J.J., Civin C.I., Carroll A.J., Look A.T., Behm F.G., Land V.J., Pullen D.J., Crist W.M. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study. J. Clin. Oncol. 8:1990;1389.
19. Boue D.R., LeBien T.W. Expression and structure of CD22 in acute leukemia. Blood. 71:1988;1480.
20. Bradstock K.F., Janossy G., Tidman N., Papageorgiou E.S., Prentice H.G., Willoughby M., Hoffbrand A.V. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk. Res. 5:1981;301.
21. Breton-Gorius J., Lewis J.C., Guichard J., Kieffer N., Vainchenker W. Monoclonal antibodies specific for human platelet membrane glycoproteins bind to monocytes by focal absorption of platelet membrane fragments: an ultrastructural immunogold study. Leukemia. 1:1987;131.
22. Breton-Gorius J., Villeval J.L., Kieffer N., Mitjavila M.T., Guichard J., Vainchenker W. Limits of phenotypic markers for the diagnosis of megakaryoblastic leukemia. Blood Cells. 15:1989;259.
23. Brisco J., Hughes E., Neoh S.H., Sykes P.J., Bradstock K., Enno A., Szer J., McCaul K., Morley A.A. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 87:1996;5251.
24. Buccheri V., Mihaljevic B., Matutes E., Dyer M.J., Mason D.Y., Catovsky D. mb-1: a new marker for B-lineage lymphoblastic leukemia. Blood. 82:1993;853.
25. Buccheri V., Shetty V., Yoshida N., Morilla R., Matutes E., Catovsky D. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Br. J. Haematol. 80:1992;62.
26. Cabezudo E., Carrara P., Morilla R., Matutes E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica. 84:1999;413.
27. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood. 87:1996;2615.
28. Campana D., Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 38:1999;139.
29. Campana D., Coustan-Smith E., Behm F.G., Goorha R. Normal and aberrant T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Ludwig W.-D., Thiel E. Recent Advances in Cell Biology of Acute Leukemia. 1993;19 Springer, Berlin.
30. Campana D., Coustan-Smith E., Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood. 76:1990;163.
31. Campana D., Hansen-Hagge T.E., Matutes E., Coustan-Smith E., Yokota S., Shetty V., Bartram C.R., Janossy G. Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. Leukemia. 4:1990;620.
32. Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 85:1995;1416.
33. Campana D., Thompson J.S., Amlot P., Brown S., Janossy G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J. Immunol. 138:1987;648.
34. Campana D., van Dongen J.J., Mehta A., Coustan-Smith E., Wolvers-Tettero I.L., Ganeshaguru K., Janossy G. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood. 77:1991;1546.
35. Catovsky D. Chronic lymphoproliferative disorders. Curr. Opin. Oncol. 7:1995;3.
36. Cave H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., Bakkus M., Thielemans K., Grandchamp B., Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. New Engl. J. Med. 339:1998;591.
37. Ciudad J., San Miguel J.F., Lopez-Berges M.C., Vidriales B., Valverde B., Ocqueteau M., Mateos G., Caballero M.D., Hernandez J., Moro M.J., Mateos M.V., Orfao A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J. Clin. Oncol. 16:1998;3774.
38. Claxton D.F., Reading C.L., Nagarajan L., Tsujimoto Y., Andersson B.S., Estey E., Cork A., Huh Y.O., Trujillo J., Deisseroth A.B. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood. 80:1992;582.
39. Coustan-Smith E., Behm F.G., Hurwitz C.A., Rivera G.K., Campana D. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia. 7:1993;853.
40. Coustan-Smith E., Behm F.G., Sanchez J., Boyett J.M., Hancock M.L., Raimondi S.C., Rubnitz J.E., Rivera G.K., Sandlund J.T., Pui C.H., Campana D. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 351:1998;550.
41. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., Buchbinder A., Budman D., Dittmar K., Kolitz J., Lichtman S.M., Schulman P., Vinciguerra V.P., Rai K.R., Ferrarini M., Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1999;1840.
42. DiGiuseppe J.A., Borowitz M.J. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin. Oncol. 25:1998;6.
43. Drach J., Drach D., Glassl H., Gattringer C., Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry. 13:1992;893.
44. Drexler H.G. Classification of acute myeloid leukemias - a comparison of FAB and immunophenotyping. Leukemia. 1:1987;697.
45. Drexler H.G., Messmore H.L., Menon M., Minowada J. A case of TdT-positive B-cell acute lymphoblastic leukemia. Am. J. Clin. Pathol. 85:1986;735.
46. Drexler H.G., Thiel E., Ludwig W.D. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 5:1991;637.
47. Drexler H.G., Thiel E., Ludwig W.D. Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia. 7:1993;489.
48. Erber W.N., Breton-Gorius J., Villeval J.L., Oscier D.G., Bai Y., Mason D.Y. Detection of cells of megakaryocyte lineage in haematological malignancies by immuno-alkaline phosphatase labelling cell smears with a panel of monoclonal antibodies. Br. J. Haematol. 65:1987;87.
49. Farahat N., Morilla A., Owusu-Ankomah K., Morilla R., Pinkerton C.R., Treleaven J.G., Matutes E., Powles R.L., Catovsky D. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br. J. Haematol. 101:1998;158.
50. Finlay J.L., Borcherding W. Acute B-lymphocytic leukemia with L1 morphology: a report of two pediatric cases. Leukemia. 2:1988;60.
51. Freedman A.S., Nadler L.M. Immunologic markers in non-Hodgkin's lymphoma. Hematol. Oncol. Clin. North Am. 5:1991;871.
52. Gagnon G.A., Childs C.C., LeMaistre A., Keating M., Cork A., Trujillo J.M., Nellis K., Freireich E., Stass S.A. Molecular heterogeneity in acute leukemia lineage switch. Blood. 74:1989;2088.
53. Garcia-Sanz R., Orfao A., Gonzalez M., Tabernero M.D., Blade J., Moro M.J., Fernandez-Calvo J., Sanz M.A., Perez-Simon J.A., Rasillo A., Miguel J.F. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 93:1999;1032.
54. Gluck W.L., Bigner S.H., Borowitz M.J., Brenckman W.D.J. Acute lymphoblastic leukemia of Burkitt's type (L3 ALL) with 8;22 and 14;18 translocations and absent surface immunoglobulins. Am. J. Clin. Pathol. 85:1986;636.
55. Greaves M., Paxton A., Janossy G., Pain C., Johnson S., Lister T.A. Acute lymphoblastic leukaemia associated antigen. III. Alterations in expression during treatment and in relapse. Leuk. Res. 4:1980;1.
56. Griesinger F., Piro-Noack M., Kaib N., Falk M., Renziehausen A., Troff C., Grove D., Schnittger S., Buchner T., Ritter J., Hiddemann W., Wormann B. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br. J. Haematol. 105:1999;241.
57. Gruhn B., Hongeng S., Yi H., Hancock M.L., Rubnitz J.E., Neale G.A., Kitchingman G.R. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia. 12:1998;675.
58. Harada H., Kawano M.M., Huang N., Harada Y., Iwato K., Tanabe O., Tanaka H., Sakai A., Asaoku H., Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 81:1993;2658.
59. Hunger S.P., Fall M.Z., Camitta B.M., Carroll A.J., Link M.P., Lauer S.J., Mahoney D.H., Pullen D.J., Shuster J.J., Steuber C.P., Cleary M.L. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 91:1998;1021.
60. Hurwitz C.A., Raimondi S.C., Head D., Krance R., Mirro J.J., Kalwinsky D.K., Ayers G.D., Behm F.G. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 80:1992;3182.
61. Hurwitz C.A., Raimondi S.C., Head D., Krance R., Mirro J.J., Kalwinsky D.K., Ayers G.D., Behm F.G. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 80:1992;3182.
62. Jacquy C., Delepaut B., Van Daele S., Vaerman J.L., Zenebergh A., Brichard B., Vermylen C., Cornu G., Martiat P. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br. J. Haematol. 98:1997;140.
63. Janossy G., Coustan-Smith E., Campana D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 3:1989;170.
64. Keating M.J. Chronic lymphocytic leukemia. Semin. Oncol. 26:1999;107.
65. Kishimoto T., Kikutani H., von dem Borne A.E.G., Goyert S., Mason D.Y., Miyasaka M., Moretta L., Okumura K., Shaw S., Springer T.A., Sugamura K., Zola H. Leucocyte Typing. Vol. VI:1998;Garland, New York.
66. Kita K., Nakase K., Miwa H., Masuya M., Nishii K., Morita N., Takakura N., Otsuji A., Shirakawa S., Ueda T. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 80:1992;470.
67. Knapp W., Strobl H., Majdic O. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry. 18:1994;187.
68. Koehler M., Behm F.G., Shuster J., Crist W., Borowitz M., Look A.T., Head D., Carroll A.J., Land V., Steuber P. Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: a Pediatric Oncology Group study. Leukemia. 7:1993;2064.
69. Kwong Y.L., Chan A.C., Liang R.H. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol. Oncol. 15:1997;71.
70. Lanza F., Castoldi G.L., Castagnari B., Todd R.F., Moretti S., Spisani S., Latorraca A., Focarile E., Roberti M.G., Traniello S. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br. J. Haematol. 103:1998;110.
71. Lauer S., Piaskowski V., Camitta B., Casper J. Bone marrow and extramedullary variations of cell membrane antigen expression in childhood lymphoid neoplasias at relapse. Leuk. Res. 6:1982;769.
72. Link M.P., Stewart S.J., Warnke R.A., Levy R. Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. J. Clin. Invest. 76:1985;248.
73. Lo Coco F., Avvisati G., Diverio D., Biondi A., Pandolfi P.P., Alcalay M., De Rossi G., Petti M.C., Cantu-Rajnoldi A., Pasqualetti D. Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype. Br. J. Haematol. 78:1991;494.
74. Lo Coco F., Diverio D., Pandolfi P.P., Biondi A., Rossi V., Avvisati G., Rambaldi A., Arcese W., Petti M.C., Meloni G. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet. 340:1992;1437.
75. Macedo A., Orfao A., Gonzalez M., Vidriales M.B., Lopez-Berges M.C., Martinez A., San Miguel J.F. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia. 9:1995;993.
76. Macedo A., San Miguel J.F., Vidriales M.B., Lopez-Berges M.C., Garcia-Marcos M.A., Gonzalez M., Landolfi C., Orfao A. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J. Clin. Pathol. 49:1996;15.
77. Mason D.Y., Cordell J.L., Tse A.G., van Dongen J.J., van Noesel C.J., Micklem K., Pulford K.A., Valensi F., Comans-Bitter W.M., Borst J. The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J. Immunol. 147:1991;2474.
78. Mason D.Y., Stein H., Gerdes J., Pulford K.A., Ralfkiaer E., Falini B., Erber W.N., Micklem K., Gatter K.C. Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood. 69:1987;836.
79. Matutes E., Brito-Babapulle V., Swansbury J., Ellis J., Morilla R., Dearden C., Sempere A., Catovsky D. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 78:1991;3269.
80. Matutes E., Brito-Babapulle V., Worner I., Sainati L., Foroni L., Catovsky D. T-cell chronic lymphocytic leukaemia: the spectrum of mature T-cell disorders. Nouv. Rev. Fr. Hematol. 30:1988;347.
81. Matutes E., Morilla R., Owusu-Ankomah K., Houliham A., Meeus P., Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk. Lymphoma. 14:(Suppl. 1):1994;57.
82. Matutes E., Morilla R., Owusu-Ankomah K., Houlihan A., Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 83:1994;1558.
83. Matutes E., Owusu-Ankomah K., Morilla R., Garcia M.J., Houlihan A., Que T.H., Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 8:1994;1640.
84. Mirro J., Zipf T.F., Pui C.H., Kitchingman G., Williams D., Melvin S., Murphy S.B., Stass S. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood. 66:1985;1115.
85. Mufti G.J., Hamblin T.J., Oscier D.G., Johnson S. Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. Blood. 62:1983;1142.
86. Neale G.A., Coustan-Smith E., Pan Q., Chen X., Gruhn B., Stow P., Behm F.G., Pui C.H., Campana D. Detection of minimal residual disease in childhood acute lymphoblastic leukemia with immunologic and molecular methods: a comparative study. Blood. 92:(Suppl. 1):1998;394a.
87. Neale G.A., Menarguez J., Kitchingman G.R., Fitzgerald T.J., Koehler M., Mirro J.J., Goorha R.M. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood. 78:1991;739.
88. Neglia J.P., Meadows A.T., Robison L.L., Kim T.H., Newton W.A., Ruymann F.B., Sather H.N., Hammond G.D. Second neoplasms after acute lymphoblastic leukemia in childhood. New Engl. J. Med. 325:1991;1330.
89. Nucifora G., Larson R.A., Rowley J.D. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 82:1993;712.
90. Orfao A., Chillon M.C., Bortoluci A.M., Lopez-Berges M.C., Garcia-Sanz R., Gonzalez M., Tabernero M.D., Garcia-Marcos M.A., Rasillo A.I., Hernandez-Rivas J., San Miguel J.F. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML- RARa gene rearrangements. Haematologica. 84:1999;405.
91. Paietta E., Andersen J., Gallagher R., Bennett J., Yunis J., Cassileth P., Rowe J., Wiernik P.H. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 8:1994;1108.
92. Paietta E., Andersen J., Yunis J., Rowe J.M., Cassileth P.A., Tallman M.S., Bennett J.M., Wiernik P.H. Acute myeloid leukaemia expressing the leucocyte integrin CD11b - a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group. Br. J. Haematol. 100:1998;265.
93. Paietta E., Wiernik P.H., Andersen J., Bennett J., Yunis J. Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression [letter]. Blood. 82:1993;2595.
94. Pangalis G.A., Angelopoulou M.K., Vassilakopoulos T.P., Siakantaris M.P., Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin. Hematol. 36:1999;104.
95. Pope B., Brown R.D., Gibson J., Petersen A., Wiley J., Joshua D.E. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. Leuk. Lymphoma. 27:1997;83.
96. Porwit-MacDonald A., Janossy G., Ivory K., Swirsky D., Peters R., Wheatley K., Walker H., Turker A., Goldstone A.H., Burnett A. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood. 87:1996;1162.
97. Privitera E., Kamps M.P., Hayashi Y., Inaba T., Shapiro L.H., Raimondi S.C., Behm F., Hendershot L., Carroll A.J., Baltimore D. Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 79:1992;1781.
98. Pui C.H., Behm F.G., Singh B., Schell M.J., Williams D.L., Rivera G.K., Kalwinsky D.K., Sandlund J.T., Crist W.M., Raimondi S.C. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 75:1990;174.
99. Pui C.H., Behm F.G., Singh B., Rivera G.K., Schell M.J., Roberts W.M., Crist W.M., Mirro J.J. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood. 75:1990;198.
100. Pui C.H., Ribeiro R.C., Hancock M.L., Rivera G.K., Evans W.E., Raimondi S.C., Head D.R., Behm F.G., Mahmoud M.H., Sandlund J.T. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New Engl. J. Med. 325:1991;1682.
101. Pui C.H., Raimondi S.C., Head D.R., Schell M.J., Rivera G.K., Mirro J.J., Crist W.M., Behm F.G. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood. 78:1991;1327.
102. Pui C.H., Frankel L.S., Carroll A.J., Raimondi S.C., Shuster J.J., Head D.R., Crist W.M., Land V.J., Pullen D.J., Steuber C.P. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood. 77:1991;440.
103. Pui C.H., Behm F.G., Crist W.M. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 82:1993;343.
104. Pui C.H., Hancock M.L., Head D.R., Rivera G.K., Look A.T., Sandlund J.T., Behm F.G. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood. 82:1993;889.
105. Pui C.H., Rivera G.K., Hancock M.L., Raimondi S.C., Sandlund J.T., Mahmoud H.H., Ribeiro R.C., Furman W.L., Hurwitz C.A., Crist W.M. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia. 7:1993;35.
106. Pui C.H., Raimondi S.C., Hancock M.L., Rivera G.K., Ribeiro R.C., Mahmoud H.H., Sandlund J.T., Crist W.M., Behm F.G. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J. Clin. Oncol. 12:1994;2601.
107. Pui C.H., Campana D., Crist W.M. Toward a clinically useful classification of the acute leukemias. Leukemia. 9:1995;2154.
108. Radich J., Gehly G., Lee A., Avery R., Bryant E., Edmands S., Gooley T., Kessler P., Kirk J., Ladne P., Thomas E.D., Appelbaum F.R. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 89:1997;2602.
109. Raghavachar A., Thiel E., Bartram C.R. Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood. 70:1987;1079.
110. Rawstron A.C., Owen R.G., Davies F.E., Johnson R.J., Jones R.A., Richards S.J., Evans P.A., Child J.A., Smith G.M., Jack A.S., Morgan G.J. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 97:1997;46.
111. Reading C.L., Estey E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen L.W., O'Brien M.C., Baron S., Deisseroth A.B. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 81:1993;3083.
112. Rothe G., Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia. 10:1996;877.
113. Sang B.C., Shi L., Dias P., Liu L., Wei J., Wang Z.X., Monell C.R., Behm F., Gruenwald S. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Blood. 89:1997;2909.
114. San Miguel J.F., Martinez A., Macado A., Vidriales M.B., Lopez-Berges C., Gonzalez M., Caballero D., Garcia-Marcos M.A., Ramos F., Fernandez-Calvo J., Calmuntia M.J., Diaz-Mediavilla J., Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 90:1997;2465.
115. Secker-Walker L., Stewart E., Norton J., Campana D., Thomas A., Hoffbrand V., Prentice G. Multiple chromosome abnormalities in a drug resistant TdT positive B-cell leukemia. Leuk. Res. 11:1987;155.
116. Seymour J.F., Pierce S.A., Kantarjian H.M., Keating M.J., Estey E.H. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 8:1994;823.
117. Shuster J.J., Falletta J.M., Pullen D.J., Crist W.M., Humphrey G.B., Dowell B.L., Wharam M.D., Borowitz M. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 75:1990;166.
118. Sievers E.L., Lange B.J., Buckley J.D., Smith F.O., Wells D.A., Daigneault-Creech C.A., Shults K.E., Bernstein I.D., Loken M.R. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J. Natl. Cancer Inst. 88:1996;1483.
119. Smith F.O., Lampkin B.C., Versteeg C., Flowers D.A., Dinndorf P.A., Buckley J.D., Woods W.G., Hammond G.D., Bernstein I.D. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood. 79:1992;2415.
120. Solary E., Casasnovas R.O., Campos L., Bene M.C., Faure G., Maingon P., Falkenrodt A., Lenormand B., Genetet N. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR - phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia. 6:1992;393.
121. Stass S., Mirro J., Melvin S., Pui C.H., Murphy S.B., Williams D. Lineage switch in acute leukemia. Blood. 64:1984;701.
122. Thiel E., Kranz B.R., Raghavachar A., Bartram C.R., Loffler H., Messerer D., Ganser A., Ludwig W.D., Buchner T., Hoelzer D. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood. 73:1989;1247.
123. Thomas X., Campos L., Archimbaud E., Shi Z.H., Treille-Ritouet D., Anglaret B., Fiere D. Surface marker expression in acute myeloid leukaemia at first relapse. Br. J. Haematol. 81:1992;40.
124. Uckun F.M., Sather H.N., Gaynon P.S., Arthur D.C., Trigg M.E., Tubergen D.G., Nachman J., Steinherz P.G., Sensel M.G., Reaman G.H. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 90:1997;28.
125. Uckun F.M., Steinherz P.G., Sather H., Trigg M., Arthur D., Tubergen D., Gaynon P., Reaman G. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 88:1996;4288.
126. van Dongen J.J., Breit T.M., Adriaansen H.J., Beishuizen A., Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia. 6:(Suppl. 1):1992;47.
127. van Dongen J.J., Krissansen G.W., Wolvers-Tettero I.L., Comans-Bitter W.M., Adriaansen H.J., Hooijkaas H., Van Wering E.R., Terhorst C. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 71:1988;603.
128. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., Biondi A., Pongers-Willemse M.J., Corral L., Stolz F., Schrappe M., Masera G., Kamps W.A., Gadner H., Van Wering E.R., Ludwig W.-D., Basso G., de Bruijn M.A.C., Cazzaniga G., Hettinger K., van der Does-van den Berg A., Hop W.C.J., Riehm H., Bartram C.R. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 352:1998;1731.
129. Van Wering E.R., Beishuizen A., Roeffen E.T., van der Linden-Schrever B.E., Verhoeven M.A., Hahlen K., Hooijkaas H., van Dongen J.J. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia. 9:1995;1523.
130. Venditti A., Del Poeta G., Buccisano F., Tamburini A., Cox M.C., Stasi R., Bruno A., Aronica G., Maffei L., Suppo G., Simone M.D., Forte L., Cordero V., Postorino M., Tufilli V., Isacchi G., Masi M., Papa G., Amadori S. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood. 89:1997;621.
131. Vidriales M.B., Orfao A., Gonzalez M., Hernandez J.M., Lopez-Berges M.C., Garcia M.A., Canizo M.C., Caballero M.D., Macedo A., Landolfi C. Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukemia. Leukemia. 7:1993;2026.
132. Vogler L.B., Crist W.M., Bockman D.E., Pearl E.R., Lawton A.R., Cooper M.D. Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. New Engl. J. Med. 298:1978;872.
133. Walle A.J., Al-Katib A., Wong G.Y., Jhanwar S.C., Chaganti R.S., Koziner B. Multiparameter characterization of L3 leukemia cell populations. Leuk. Res. 11:1987;73.
134. Weir E.G., Cowan K., LeBeau P., Borowitz M.J. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia. 13:1999;558.
135. Yokota S., Hansen-Hagge T.E., Ludwig W.D., Reiter A., Raghavachar A., Kleihauer E., Bartram C.R. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood. 77:1991;331.
136. Zupo S., Isnardi L., Megna M., Massara R., Malavasi F., Dono M., Cosulich E., Ferrarini M. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood. 88:1996;1365.